中文产业新闻精选评分64Chinese source
传奇生物CARVYKTI在CARTITUDE-2队列A中显示50% RRMM患者单次输注五年后无进展生存
2026 IMS | 传奇生物CARVYKTI 最新数据显示50% RRMM患者在单次输注五年后保持无疾病进展生存
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.